134 related articles for article (PubMed ID: 11917058)
1. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2002 Apr; 17(4):637-44. PubMed ID: 11917058
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
[TBL] [Abstract][Full Text] [Related]
3. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients.
Borawski J; Pawlak K; Naumnik B; Myśliwiec M
Ren Fail; 2002 Nov; 24(6):825-37. PubMed ID: 12472204
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response.
Borawski J; Naumnik B; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Jul; 16(7):1442-7. PubMed ID: 11427638
[TBL] [Abstract][Full Text] [Related]
5. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients.
Borawski J; Naumnik B; Pawlak K; Myśliwiec M
Nephrol Dial Transplant; 2001 Apr; 16(4):787-92. PubMed ID: 11274275
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
Borawski J; Myśliwiec M
Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
[TBL] [Abstract][Full Text] [Related]
7. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin.
Borawski J; Naumnik B; Myśliwiec M
Kidney Int; 2003 Dec; 64(6):2229-37. PubMed ID: 14633147
[TBL] [Abstract][Full Text] [Related]
8. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
[TBL] [Abstract][Full Text] [Related]
9. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
Sitter T; Bergner A; Schiffl H
Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
Borawski J; Naumnik B; Mysliwiec M
Clin Appl Thromb Hemost; 2002 Oct; 8(4):359-67. PubMed ID: 12516686
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
12. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients.
Małyszko J; Wołczyński S; Zbroch E; Brzósko S; Małyszko J; Myśliwiec M
Nephron; 2002 Mar; 90(3):282-9. PubMed ID: 11867949
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease.
Malatino LS; Mallamaci F; Benedetto FA; Bellanuova I; Cataliotti A; Tripepi G; Zoccali C
Am J Kidney Dis; 2000 Nov; 36(5):945-52. PubMed ID: 11054350
[TBL] [Abstract][Full Text] [Related]
16. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
[TBL] [Abstract][Full Text] [Related]
17. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
18. [Blood serum hepatocyte growth factor in children with chronic renal failure treated with CAPD and HD].
Szprynger K; Szczepańska M; Morawiec-Knysak A; Dyduch A
Pol Merkur Lekarski; 2000 Apr; 8(46):270-1. PubMed ID: 10897645
[TBL] [Abstract][Full Text] [Related]
19. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
20. Serum hepatocyte growth factor levels in patients with chronic renal failure.
Sugimura K; Kim T; Goto T; Kasai S; Takemoto Y; Matsuda J; Yoshimoto M; Yamagami S; Kishimoto T
Nephron; 1995; 70(3):324-8. PubMed ID: 7477621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
